How One Professor Built Two Billion-Dollar Biotechs
Professor Ugur Sahin, M.D., Ph.D. never wanted to be an entrepreneur. Yet, today he’s the cofounder and CEO of BioNTech, a publicly traded German biotech aspiring to develop individualized cancer medicines. It was a surprising career path switch.
A Chat On Biosimilars With Sandoz’s U.S. President Carol Lynch
Carol Lynch, president of Sandoz U.S. and head of North America, fields biosimilars-related questions from the audience at the 2020 BIO CEO & Investor Conference.
BioEclipse Therapeutics — More Than Just A Story Of Rebranding
In 2006, Pamela Contag, Ph.D. cofounded ConcentRx, but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. The CEO talks about what she learned in those 10 years on that difficult business journey
Former Biopharma CEO Develops Novel Solution For The “Valley Of Death”
I recently met a scientist who had experienced the valley of death firsthand. And rather than have her valley experience be her demise, she instead opted to develop a novel solution. This is her story.
5 Biopharma Execs Reveal Corporate Culture Best Practices
“Corporate culture will soon be the number one reason why an employee stays or leaves a company.” It’s a comment made to start off a roundtable discussion at the 2020 JPM conference, and we have the details of the discussion here.
Building GSK Oncology R&D
Axel Hoos, M.D., Ph.D., SVP oncology and R&D governance chair, provides an update and the context of GSK’s R&D strategy.
The Story Of Arrowhead Pharmaceuticals’ Adversity Odyssey
Chris Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals, discusses taking over a biopharmaceutical company shortly before the Great Recession along with other avenues of adversity faced (e.g., FDA hold on a Phase 2 trial) toward bringing this RNAi company to the brink of success.
Why You Need People Like Jana Spes At Your Company
Industry veteran Jana Spes provides some uniquely qualified analysis and guidance on the outsourcing industry and working with CDMOs. Don’t be surprised if you come away thinking for your next outsourcing operations hire, specialization is out, and the Spes model is in.
Jeff Albers’ Blueprint For Blueprint Medicines
Jeff Albers, president and CEO of Blueprint Medicines, discusses his approach to ensuring the biopharma is commercial ready should it garner some pivotal FDA approvals.
A Biopharma That Had To Pivot Twice To Forge Ahead
Not many thriving companies experience disappointing clinical trial results, jump into an entirely new therapeutic area, and emerge with investor support and renewed hope for an entirely different class of patients. Millendo has done it twice.
The Perilous Development Of A Potential Biologic Blockbuster
CytoDyn's leronlimab is under FDA review for Breakthrough Therapy status. Its path from forgotten molecule to near market readiness was riddled with financial and process challenges.
Allogene Therapeutics — The Juggernaut Built On Kite’s Flight
David Chang, M.D., Ph.D., CEO and cofounder of Allogene Therapeutics, shares how the successful exit from Kite Pharma (acquired by Gilead for $11.9 billion in 2017) led to the building of Allogene, a $3.4 billion clinical-stage biopharma developing allogeneic CAR-T therapy.
Why John Sculley Views Healthcare As His “Noble Cause”
John Sculley, the former CEO of Apple who is now an entrepreneur and investor in high-tech startups, discusses where he sees opportunity in the healthcare industry, along with the leaders he views as being just as visionary as Steve Jobs, if not more so.
J&J And Merck Detail How They Are Investing For Impact
Two Big Pharma executives explain how their organizations are investing for impact.
BEYOND THE PRINTED PAGE
A Biopharma CEO Not Focused On Stock Price
BioNTech’s founder and CEO, Ugur Sahin, M.D., Ph.D., subject of an upcoming feature in Life Science Leader, provides perspective on the company’s IPO and stock price as a metric.
Disappointments In Alzheimer’s Therapeutic Development — A Conversation With John LaMattina
A question from a reader for Life Science Leader's popular monthly Ask The Board column, prompts a Q&A discussion with John LaMattina, Ph.D., on the retreat from neuroscience R&D.
Pamela Contag — A Veteran Biopharma Entrepreneur Worth Getting To Know
Veteran biopharma entrepreneur Pamela Contag discusses beneficial attributes for startup CEOs, along with some advice for women executives.
LIFE SCIENCE LEADER BLOGS
Coordinates of COVID-19 Press Aligos Therapeutics To Pivot On Multiple Fronts
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses how his company pivoted as a result of the current pandemic, including announced efforts to develop a vaccine for COVID-19.
The Reality Of Living In A COVID19 World
Chief editor Rob Wright shares the difficulty associated with living, working and trying to be productive during the COVID-19 pandemic.